INS and type 1 diabetes mellitus: Reflecting the secondary role of autoantibodies in the progression of T1DM, rituximab-mediated B-cell depletion was found to decrease HbA1c, reduce insulin requirements, and slow the decline of C peptide levels in patients with T1DM [240].